These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

582 related articles for article (PubMed ID: 29325642)

  • 41. Lipoprotein apheresis for lipoprotein(a) and cardiovascular disease.
    Moriarty PM; Gray JV; Gorby LK
    J Clin Lipidol; 2019; 13(6):894-900. PubMed ID: 31753721
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Elevated expression of lipoprotein-associated phospholipase A2 in calcific aortic valve disease: implications for valve mineralization.
    Mahmut A; Boulanger MC; El Husseini D; Fournier D; Bouchareb R; Després JP; Pibarot P; Bossé Y; Mathieu P
    J Am Coll Cardiol; 2014 Feb; 63(5):460-9. PubMed ID: 24161325
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lp(a): Addressing a Target for Cardiovascular Disease Prevention.
    Vasquez N; Joshi PH
    Curr Cardiol Rep; 2019 Jul; 21(9):102. PubMed ID: 31367887
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cardiovascular Disease, Mortality Risk, and Healthcare Costs by Lipoprotein(a) Levels According to Low-density Lipoprotein Cholesterol Levels in Older High-risk Adults.
    Zhao Y; Delaney JA; Quek RG; Gardin JM; Hirsch CH; Gandra SR; Wong ND
    Clin Cardiol; 2016 Jul; 39(7):413-20. PubMed ID: 27177347
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Emerging Therapeutic Options for Lowering of Lipoprotein(a): Implications for Prevention of Cardiovascular Disease.
    Boffa MB
    Curr Atheroscler Rep; 2016 Dec; 18(12):69. PubMed ID: 27761705
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The journey towards understanding lipoprotein(a) and cardiovascular disease risk: are we there yet?
    Boffa MB; Koschinsky ML
    Curr Opin Lipidol; 2018 Jun; 29(3):259-267. PubMed ID: 29528858
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pathological significance of lipoprotein(a) in aortic valve stenosis.
    Yu B; Khan K; Hamid Q; Mardini A; Siddique A; Aguilar-Gonzalez LP; Makhoul G; Alaws H; Genest J; Thanassoulis G; Cecere R; Schwertani A
    Atherosclerosis; 2018 May; 272():168-174. PubMed ID: 29614432
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evidence-based assessment of lipoprotein(a) as a risk biomarker for cardiovascular diseases - Some answers and still many questions.
    Kotani K; Serban MC; Penson P; Lippi G; Banach M
    Crit Rev Clin Lab Sci; 2016 Dec; 53(6):370-8. PubMed ID: 27173621
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biology, pathophysiology and current therapies that affect lipoprotein (a) levels.
    Rawther T; Tabet F
    J Mol Cell Cardiol; 2019 Jun; 131():1-11. PubMed ID: 30986377
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The role of Lipoprotein(a) in cardiovascular disease: Current concepts and future perspectives.
    Vavuranakis MA; Jones SR; Cardoso R; Gerstenblith G; Leucker TM
    Hellenic J Cardiol; 2020; 61(6):398-403. PubMed ID: 33039574
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of Lipoprotein(a)-Levels in Patients ≥70 Years of Age With Versus Without Aortic Valve Stenosis.
    Mahabadi AA; Kahlert P; Kahlert HA; Dykun I; Balcer B; Forsting M; Heusch G; Rassaf T
    Am J Cardiol; 2018 Aug; 122(4):645-649. PubMed ID: 29954600
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population.
    Kamstrup PR; Tybjærg-Hansen A; Nordestgaard BG
    J Am Coll Cardiol; 2014 Feb; 63(5):470-7. PubMed ID: 24161338
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association of Mild to Moderate Aortic Valve Stenosis Progression With Higher Lipoprotein(a) and Oxidized Phospholipid Levels: Secondary Analysis of a Randomized Clinical Trial.
    Capoulade R; Yeang C; Chan KL; Pibarot P; Tsimikas S
    JAMA Cardiol; 2018 Dec; 3(12):1212-1217. PubMed ID: 30476957
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations.
    Shah NP; Pajidipati NJ; McGarrah RW; Navar AM; Vemulapalli S; Blazing MA; Shah SH; Hernandez AF; Patel MR
    Am J Cardiol; 2020 Jul; 126():94-102. PubMed ID: 32336532
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Increased cardiovascular risk associated with hyperlipoproteinemia (a) and the challenges of current and future therapeutic possibilities.
    Fras Z
    Anatol J Cardiol; 2020 Jan; 23(2):60-69. PubMed ID: 32011323
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lipoprotein apheresis for Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease--Additional particular aspects of the Pro(a)LiFe multicenter trial.
    Klingel R; Heibges A; Fassbender C
    Atheroscler Suppl; 2015 May; 18():35-40. PubMed ID: 25936302
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines.
    Klingel R; Heibges A; Fassbender C;
    Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):38-43. PubMed ID: 28185214
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Future Directions to Establish Lipoprotein(a) as a Treatment for Atherosclerotic Cardiovascular Disease.
    Stein EA; Raal F
    Cardiovasc Drugs Ther; 2016 Feb; 30(1):101-8. PubMed ID: 26861250
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lipoprotein(a): Evidence for Role as a Causal Risk Factor in Cardiovascular Disease and Emerging Therapies.
    Bhatia HS; Wilkinson MJ
    J Clin Med; 2022 Oct; 11(20):. PubMed ID: 36294361
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oxidized Phospholipids and Risk of Calcific Aortic Valve Disease: The Copenhagen General Population Study.
    Kamstrup PR; Hung MY; Witztum JL; Tsimikas S; Nordestgaard BG
    Arterioscler Thromb Vasc Biol; 2017 Aug; 37(8):1570-1578. PubMed ID: 28572160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.